{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:35:21Z","timestamp":1792852521622,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fujian Natural Science Foundation for Distinguished Yong Scholars","award":["2022D005"],"award-info":[{"award-number":["2022D005"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023CXB001"],"award-info":[{"award-number":["2023CXB001"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8207196"],"award-info":[{"award-number":["8207196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272037"],"award-info":[{"award-number":["82272037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422039"],"award-info":[{"award-number":["82422039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Scientific Research Program for Yong Scholars in Fujian","award":["2021ZQNZD016"],"award-info":[{"award-number":["2021ZQNZD016"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,11,28]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, <jats:sup>68<\/jats:sup>Ga\/<jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub>, which demonstrated increased tumor uptake and prolonged retention in various cancers. However, further exploration is required to understand the therapeutic efficacy and underlying mechanisms of combining <jats:sup>68<\/jats:sup>Ga\/<jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> radioligand therapy with PD-1\/PD-L1 immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Regarding the change in PD-L1 expression and DNA double-strand breaks induced by radiopharmaceuticals, CT26-FAP tumor cells were incubated with <jats:sup>68<\/jats:sup>Ga and <jats:sup>177<\/jats:sup>Lu labeled DOTA-2P(FAPI)<jats:sub>2<\/jats:sub>, respectively. Monotherapy with <jats:sup>68<\/jats:sup>Ga-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub>, <jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub>, and PD-L1 immunotherapy as well as combination therapy (<jats:sup>68<\/jats:sup>Ga\/<jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> and PD-L1 immunotherapy) were tested and evaluated to evaluate in vivo antitumor efficacy. Furthermore, immunohistochemical staining and single-cell RNA sequencing were used to analyze changes in the tumor microenvironment (TME) and elucidate the underlying mechanisms of action of this combination therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our findings indicated that FAP-targeting radiopharmaceuticals can induce DNA double-strand breaks and upregulate PD-L1 expression, with <jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> proving to be more effective than <jats:sup>68<\/jats:sup>Ga-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub>. Both <jats:sup>68<\/jats:sup>Ga-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> and <jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> radiopharmaceuticals significantly improved therapeutic outcomes when combined with anti-PD-L1 monoclonal antibody (\u03b1PD-L1 mAb). Notably, the combination of <jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> with \u03b1PD-L1 mAb immunotherapy eliminated tumors in mouse models. Mice treated with this regimen not only exhibited exceptional responses to the initial immune checkpoint inhibitor therapy but also showed 100% tumor rejection on subsequent tumor cell re-inoculation. Further mechanistic studies have shown that <jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub> combined with \u03b1PD-L1 mAb can reprogram the TME, enhancing antitumor intercellular communication, which activates antitumor-related intercellular contacts such as FasL-Fas interactions between T cells and NK cells with tumor cells and increasing the proportion of infiltrating CD8+ T-cells while reducing regulatory T cells and inhibiting tumor progression. Our research also demonstrates that mature neutrophils play a role in enhancing the efficacy of the combined therapy, as shown in neutrophil-blocking experiments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study robustly advocates for use of FAP-targeting radiopharmaceuticals, particularly <jats:sup>177<\/jats:sup>Lu-DOTA-2P(FAPI)<jats:sub>2<\/jats:sub>, alongside immunotherapy in treating FAP-positive tumors. This combination therapy transforms the TME and enables a translatable approach to increasing the sensitivity to PD-1\/PD-L1 immunotherapy, leading to improved complete remission rates and extended overall survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010212","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T23:45:14Z","timestamp":1736639114000},"page":"e010212","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["FAP-targeted radioligand therapy with <sup>68<\/sup>Ga\/<sup>177<\/sup>Lu-DOTA-2P(FAPI)<sub>2<\/sub> enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy"],"prefix":"10.1136","volume":"13","author":[{"given":"Jianhao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"},{"name":"Department of Colorectal Tumor Surgery, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"},{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"},{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-5336","authenticated-orcid":false,"given":"Qicong","family":"Luo","sequence":"additional","affiliation":[{"name":"Laboratory of Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Colorectal Tumor Surgery, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore"},{"name":"Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-8884","authenticated-orcid":false,"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025100304403773000_13.1.e010212.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.08.008"},{"key":"2025100304403773000_13.1.e010212.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2025100304403773000_13.1.e010212.3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/17474124.2021.1845141","article-title":"An update on the use of immunotherapy in patients with colorectal cancer","volume":"15","author":"Nguyen","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025100304403773000_13.1.e010212.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.05.012"},{"key":"2025100304403773000_13.1.e010212.5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025100304403773000_13.1.e010212.6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.39203"},{"key":"2025100304403773000_13.1.e010212.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2011.12.001"},{"key":"2025100304403773000_13.1.e010212.8","first-page":"733","article-title":"F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model","volume":"25","author":"Fang","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"2025100304403773000_13.1.e010212.9","doi-asserted-by":"crossref","first-page":"R199","DOI":"10.1186\/bcr643","article-title":"Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer","volume":"5","author":"Moadel","year":"2003","journal-title":"Breast Cancer Res"},{"key":"2025100304403773000_13.1.e010212.10","first-page":"334","article-title":"A pilot study treatment of malignant tumors using low-dose 18F-fluorodeoxyglucose (18F-FDG)","volume":"10","author":"Paul","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2025100304403773000_13.1.e010212.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328845"},{"key":"2025100304403773000_13.1.e010212.12","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1158\/1078-0432.CCR-22-0159","article-title":"A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti\u2013PD-L1 mAb Combination to Enhance the Antitumor Effect","volume":"28","author":"Wen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100304403773000_13.1.e010212.13","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025100304403773000_13.1.e010212.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263016"},{"key":"2025100304403773000_13.1.e010212.15","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol Pharm"},{"key":"2025100304403773000_13.1.e010212.16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00259-023-06447-2","article-title":"[68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study","volume":"51","author":"Zhou","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025100304403773000_13.1.e010212.17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.it.2021.05.001","article-title":"NLRP3 inflammasomes that induce antitumor immunity","volume":"42","author":"Zhivaki","year":"2021","journal-title":"Trends Immunol"},{"key":"2025100304403773000_13.1.e010212.18","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc6998","article-title":"The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation","volume":"6","author":"Han","year":"2021","journal-title":"Sci Immunol"},{"key":"2025100304403773000_13.1.e010212.19","doi-asserted-by":"crossref","unstructured":"Zhang G , Gao Z , Guo X , et al . CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages. J Clin Invest 2023;133. doi:10.1172\/JCI166224","DOI":"10.1172\/JCI166224"},{"key":"2025100304403773000_13.1.e010212.20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401185"},{"key":"2025100304403773000_13.1.e010212.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc928"},{"key":"2025100304403773000_13.1.e010212.22","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0563"},{"key":"2025100304403773000_13.1.e010212.23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02062-z","article-title":"Liver X receptors regulate natural killer T cell population and antitumor activity in the liver of mice","volume":"11","author":"Endo-Umeda","year":"2021","journal-title":"Sci Rep"},{"key":"2025100304403773000_13.1.e010212.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056"},{"key":"2025100304403773000_13.1.e010212.25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0338"},{"key":"2025100304403773000_13.1.e010212.26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/dna.2017.3790","article-title":"Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma","volume":"36","author":"Jiang","year":"2017","journal-title":"DNA Cell Biol"},{"key":"2025100304403773000_13.1.e010212.27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005026","article-title":"PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling","volume":"10","author":"Raja","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100304403773000_13.1.e010212.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3209"},{"key":"2025100304403773000_13.1.e010212.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167018","article-title":"Pan-cancer analysis of Kr\u00fcppel-like factor 3 and its carcinogenesis in pancreatic cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"2025100304403773000_13.1.e010212.30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","article-title":"FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2","volume":"79","author":"Xie","year":"2023","journal-title":"J Hepatol"},{"key":"2025100304403773000_13.1.e010212.31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4049\/immunohorizons.2300083","article-title":"Embigin Is Highly Expressed on CD4+ and CD8+ T Cells but Is Dispensable for Several T Cell Effector Responses","volume":"8","author":"Yang","year":"2024","journal-title":"Immunohorizons"},{"key":"2025100304403773000_13.1.e010212.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00532","article-title":"An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes in vitro","volume":"11","author":"Ohms","year":"2020","journal-title":"Front Immunol"},{"key":"2025100304403773000_13.1.e010212.33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160393"},{"key":"2025100304403773000_13.1.e010212.34","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12615"},{"key":"2025100304403773000_13.1.e010212.35","doi-asserted-by":"crossref","unstructured":"Salcher S , Sturm G , Horvath L , et al . High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Biology [Preprint] 2022. doi:10.1101\/2022.05.09.491204","DOI":"10.1101\/2022.05.09.491204"},{"key":"2025100304403773000_13.1.e010212.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766620","article-title":"Neutrophil Homeostasis and Emergency Granulopoiesis: The Example of Systemic Juvenile Idiopathic Arthritis","volume":"12","author":"Malengier-Devlies","year":"2021","journal-title":"Front Immunol"},{"key":"2025100304403773000_13.1.e010212.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0412-0"},{"key":"2025100304403773000_13.1.e010212.38","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.apsb.2023.01.020","article-title":"Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis","volume":"13","author":"Chan","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"2025100304403773000_13.1.e010212.39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jleuko\/qiad123","article-title":"The invasive margin of early-stage human colon tumors is infiltrated with neutrophils of an antitumoral phenotype","volume":"114","author":"Vadillo","year":"2023","journal-title":"J Leukoc Biol"},{"key":"2025100304403773000_13.1.e010212.40","doi-asserted-by":"publisher","DOI":"10.1038\/84205"},{"key":"2025100304403773000_13.1.e010212.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025100304403773000_13.1.e010212.42","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf6493","article-title":"Deterministic reprogramming of neutrophils within tumors","volume":"383","author":"Ng","year":"2024","journal-title":"Science"},{"key":"2025100304403773000_13.1.e010212.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1613187113"},{"key":"2025100304403773000_13.1.e010212.44","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025100304403773000_13.1.e010212.45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"key":"2025100304403773000_13.1.e010212.46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025100304403773000_13.1.e010212.47","doi-asserted-by":"publisher","DOI":"10.1080\/15401420390844483"},{"key":"2025100304403773000_13.1.e010212.48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijrobp.2016.10.043","article-title":"Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium","volume":"97","author":"Rodriguez-Ruiz","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100304403773000_13.1.e010212.49","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41557-024-01501-4","article-title":"Radiotherapy activates picolinium prodrugs in tumours","volume":"16","author":"Fu","year":"2024","journal-title":"Nat Chem"},{"key":"2025100304403773000_13.1.e010212.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.010"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:40:47Z","timestamp":1759491647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-010212"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010212","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}